Brain cancer immune therapy trial pulled before it started
NCT ID NCT05341947
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This was a very early phase 1 trial that planned to test a personalized immune cell therapy for people with recurrent glioblastoma, an aggressive brain cancer. The treatment involved taking a patient's own T cells, activating them in a lab to target cancer stem cells, and giving them back intravenously. However, the study was withdrawn before enrolling any participants, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- activated T cells
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radioactive beads take aim at brain tumours
- Two-Drug combo aims to outsmart recurrent brain tumors
- Gene-Edited immune cells take on aggressive brain tumors
- Targeted radiation delivered directly to brain tumor cavity in new trial
- Immunotherapy drug nivolumab tested in young brain cancer patients
- Laser zaps brain tumor, then immunotherapy fights back: new hope for glioblastoma?